Enzon Pharmaceuticals, INC 10-K annual reports

Viskase Holdings, Inc. (formerly Enzon Pharmaceuticals, Inc.) has filed an amendment to its 2025 Form 10-K to include required Part III information, detailing corporate governance, executive compensation, and related party transactions following its merger with Viskase Companies.

Enzon Pharmaceuticals, Inc. reported a net loss of $3.4 million for 2025, driven by merger-related expenses, as it progresses with its acquisition by Viskase Companies, Inc.

Enzon Pharmaceuticals files an amendment to its 2024 Annual Report on Form 10-K to include Part III information and an updated certification from its principal executive and financial officer.

Enzon Pharmaceuticals continues its pursuit as a public acquisition vehicle, reporting a net income of $778,000 for 2024 driven by interest income.

Enzon Pharmaceuticals has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and related matters.

Enzon Pharmaceuticals reported a net income of $1.373 million for 2023, primarily driven by interest income, while continuing its search for acquisition opportunities to utilize its net operating loss carryforwards.